Coronavirus vaccine more important for stocks than presidential election winner: Goldman Sachs

Coronavirus vaccine is more important for stocks than presidential election winner, Goldman Sachs says

Coronavirus vaccine more important for stocks than presidential election winner: Goldman Sachs Photo

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions. Legal Statement. Mutual Fund and ETF data provided by Refinitiv Lipper.

This material may not be published, broadcast, rewritten, or redistributed. ©2020 FOX News Network, LLC. All rights reserved. FAQ - Updated Privacy Policy

“The vaccine represents a more important factor than the election result for the path of equities,” wrote a team led by David Kostin, U.S. equity strategist. “The consequences of the semi-frozen economy on an uneven road to recovery will be in 3Q results.”

The firm’s reopening scale during the third quarter averaged between 4 and 5 on a scale of 1 to 10 as stay-at-home segments of the economy remained strong and back-to-business verticals struggled to gain traction. The composite score reached 71 out of 100 last week, the second-highest of the recovery, despite an increasing likelihood that a vaccine will be delayed until the middle of next year.

Superforecasters at Good Judgment say the odds of a vaccine being distributed to 25 million Americans by the first quarter of 2021 have fallen from 71% on Sept. 8 to 42%. The highest odds are for inoculation to occur in the second or third quarter next year, at 48%.

Biotech analysts at Goldman Sachs last week hosted a virtual conference where one panelist said initial data on the late-stage trials was encouraging, and that there was a greater than 90% probability of success.

The Trump administration has touted the possibility that 100 million doses could be administered to vulnerable populations by the end of this year, and said a vaccine could be widely available by mid-2021.

However, Goldman warns the biggest challenge is “convincing the population to get vaccinated,” adding that therapeutics could provide a bridge until a vaccine is widely available.

In the meantime, investors will have to grapple with third-quarter earnings that are expected to fall 21% year-over-year. Collapsing margins, a modest sales decline and a reluctance to provide guidance ahead of the election will serve as the biggest stock-market headwinds, Goldman says.

Top Tweets About The Story

Top News Stories